Abstract: Methods of treating patients for conditions such as breast augmentation, soft tissue defects, and urinary incontinence, are described. The methods include removing adipose tissue from a patient, processing a portion of the adipose tissue to obtain a substantially isolated population of cells comprising disaggregated adipose-derived stem cells, mixing the concentrated population of adipose-derived cells comprising disaggregated adipose-derived cells with a portion of unprocessed, intact, non-disaggregated adipose tissue to form a composition, and administering the composition to the patient from which the adipose tissue was removed.

Abstract: The present invention relates to novel immortalized precursor cell populations derived from embryonic stem cell populations and methods to produce such cell populations. Also disclosed is an assay to identify regulatory compounds capable of controlling cell growth for therapeutic and experimental use.

Abstract: Cells present in processed lipoaspirate tissue are used to treat patients. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Compositions that are administered to a patient include a mixture of adipose tissue and stem cells so that the composition has a higher concentration of stem cells than when the adipose tissue was removed from the patient.

Abstract: Known microbiological methods are based upon the application of pigment-forming bacteria, in particular Chromobacterium violaceum. The yield of these methods is very low, however, so that large industrial applications are not possible. However, in many fields of industry, there exists a very great demand for natural blue dyes which are substantially suitable for human digestion, which cannot be satisfied at present. Therefore, the method in accordance with the invention is characterized by the application of the newly discovered marine sediment bacterium Pseudoalteromonas species of the “Black Beauty” strain (originally deposited under file number DSM 13623 with the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH., Braunschweig, Germany pursuant to the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure). Compared to conventional methods, this marine sediment bacterium leads to an about thirteen-fold yield.

Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.

Abstract: The present invention relates generally to mammalian multipotent adult stem cells (MASC), and more specifically to methods for obtaining, maintaining and differentiating MASC to cells of multiple tissue types. Uses of MASC in the therapeutic treatment of disease are also provided.

Abstract: A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Supplemental C1-inhibitor restores the stability of M5 but not that of prouPA. Clot lysis by M5 with supplemental C1-inhibitor showed no attenuation of the rate of fibrinolysis, whereas fibrinogenolysis was prevented by C1-inhibitor. Due to higher dose tolerance of M5 with C1-inhibitor, the rate of fibrin-specific lysis reached that achievable by nonspecific fibrinolysis without inhibitor. Plasma C1-inhibitor stabilized M5 in plasma by inhibiting tcM5 and thereby non-specific plasminogen activation. At the same time, fibrin-specific plasminogen activation remained unimpaired. This unusual dissociation of effects has significant implications for improving the safety and efficacy of fibrinolysis.

Abstract: A simple search was made on the Internet. There were at least a few hundred entries. The following seem to be the best of the few dozen examined. The first page of each is cited below for identification.

Abstract: The present invention provides an agent for preventing or suppressing hepatic dysfunction which may be taken daily and continuously, has excellent safety, and is capable of effectively preventing and/or suppressing hepatic dysfunction, such as hepatocellular necrosis, and functional food, such as foods for specified health uses, for preventing or suppressing hepatic dysfunction containing this agent. The agent for preventing or suppressing hepatic dysfunction of the present invention contains whey as the active component, and the functional food for preventing or suppressing hepatic dysfunction contains the agent for preventing or suppressing hepatic dysfunction.

Abstract: The present invention provides a bacterium which has an ability to produce a useful metabolite derived from acetyl-coenzyme A, such as L-glutamic acid, L-glutamine, L-proline, L-arginine, L-leucine, L-cysteine, succinate, and polyhydroxybutyrate, wherein said bacterium is modified so that activities of D-xylulose-5-phosphate phosphoketolase and/or fructose-6-phosphate phosphoketolase are enhanced. The present invention also provides a method for producing the useful metabolite using the bacterium.

Abstract: The present invention relates to a process for producing methionine by fermentation, a process for isolating the methionine formed, the methionine-containing biomass produced in isolation, use thereof for producing a feedstuff or feed supplement, and also to the use of the isolated methionine for producing foodstuffs or feedstuffs or food supplements or feed supplements.

Abstract: Disclosed is an agent for digesting a protein highly resistant to denaturation and degradation, comprising as an active ingredient an enzyme exhibiting an activity of digesting a protein highly resistant to denaturation and degradation and having the following properties: (a) activity and substrate specificity: hydrolyzing a peptide bond of a protein highly resistant to denaturation and degradation; (b) molecular weight: 31,000 (determined by SDS-polyacrylamide gel electrophoresis using a homogeneous gel having a gel concentration of 12%); (c) isoelectric point: pI 9.3 (determined by polyacrylamide gel isoelectric focusing electrophoresis); (d) optimum pH: pH 9.0 to 10.0; and (e) optimum temperature for activity: 60 to 70° C.

Abstract: Methods and devices to process harvested skin tissue and reintroduction of the ground tissue to repair a tissue defect are disclosed. A hand-held portable tissue grinder comprising a housing and a grinding element are disclosed. The tissue grinder is used for grinding skin and subcutaneous tissue and includes a sterile polymer housing having a first opening adapted to receive the skin and subcutaneous tissue and a second opening in fluid connection with the first opening. The tissue grinder also includes a sterile grinding element disposed substantially within the housing. The grinding element includes a plurality of cutting surfaces adapted to operably engage with the housing to provide ground tissue and further includes a handle mechanism coupled to the grinding element to move the grinding element with respect to the housing to grind the skin and subcutaneous tissue, wherein the ground tissue can be removed from the housing through the second opening.

Abstract: A method of producing riboflavin by culturing riboflavin-producing microbes in a culture medium using a plant oil or an animal oil as a carbon source, forming and accumulating riboflavin therein and collecting riboflavin therefrom, wherein a carrier of a clay mineral having oil-adsorbing property, a chemically treated product thereof or a calcium compound is made present in the culture medium. The riboflavin is produced maintaining a high yield and at an increased production rate at a low cost without requiring cumbersome operations for concentrating and recovering the riboflavin. It is further allowed to recover the riboflavin by effectively utilizing the waste plant oil or the waste animal oil that is to be disposed of.

Abstract: The present invention provides a method of, and apparatus for, utilizing ultrasonic energy so as to mechanically disrupt the collagenous architecture of biological matrices in a controlled manner so that the tissue can be rapidly recellularized in continuous form. The present invention also provides for the production of tissue matrices with improved recellularization properties, cell stratification or patterning.

Abstract: The present invention relates to composition useful in growing hair. The compositions are particularly suited for re-growing hair in subjects who have experienced hair loss due to any cause. The compositions comprise essentially the lipoidic fraction of mammalian bone marrow. Methods of using the compositions and processes of preparing the lipoidic fraction for the compositions are also disclosed.

Abstract: An isolated Bacillus strain LSSAO1 is provided. When fed to a bird, this and other Bacillus strains described herein provide benefits to the birds. For example, administration of the one or more Bacillus strain can increase low G+C, gram positive bacteria in the gastrointestinal flora of the bird. These type of bacteria are increased by antibiotics and include beneficial Clostridium. Administration of the one or more Bacillus strain can also inhibit pathogen in the bird, such as E. coli, Salmonella, and Clostridium. These benefits can enhance feed conversion in poultry. Useful combinations of Bacillus strains and methods of using one or more Bacillus strain are also provided.

Abstract: Products and compositions for preventing or reducing the severity of hypertension. These products contain (a) ferulic acid or a ferulate ester, and (b) caffeic acid and/or a chlorogenic acid. The preventive or remedy can suppress a rise in blood pressure and alleviate hypertension, and is usable as a food.

Abstract: Liquid microbial starter culture that retains its initial metabolic activity during storage for extended periods of time. Such liquid starter cultures are useful in the manufacturing of food and feed products. Starter cultures of the invention include culture of lactic acid bacteria, e.g. Lactococcus species.

Abstract: The present invention relates to a process for the preparation of mycophenolate mofetil (MMF) in which an ester of mycophenolic acid (MPA) with a low-molecular-weight aliphatic alcohol is transesterified with N-(2-hydroxyethyl)morpholine in the presence of Candida antarctica lipase, and in which the MPA esterification reaction is carried out in the presence of Candida antarctica lipase using the corresponding alcohol as the solvent.